Dr Reddys Laboratories (RDY) Equity Average (2023 - 2026)
Dr Reddys Laboratories has reported Equity Average over the past 4 years, most recently at $4.0 billion for Q1 2026.
- For Q1 2026, Equity Average rose 10.78% year-over-year to $4.0 billion; the TTM value through Mar 2026 reached $4.0 billion, up 10.78%, while the annual FY2026 figure was $4.0 billion, 10.6% up from the prior year.
- Equity Average for Q1 2026 was $4.0 billion at Dr Reddys Laboratories, up from $3.6 billion in the prior quarter.
- Over five years, Equity Average peaked at $4.0 billion in Q1 2026 and troughed at $2.7 billion in Q1 2023.
- A 4-year average of $3.4 billion and a median of $3.4 billion in 2024 define the central range for Equity Average.
- Biggest five-year swings in Equity Average: increased 17.51% in 2025 and later rose 10.78% in 2026.
- Year by year, Equity Average stood at $2.7 billion in 2023, then grew by 15.8% to $3.1 billion in 2024, then increased by 17.51% to $3.6 billion in 2025, then increased by 10.78% to $4.0 billion in 2026.
- Business Quant data shows Equity Average for RDY at $4.0 billion in Q1 2026, $3.6 billion in Q1 2025, and $3.1 billion in Q1 2024.